BCR/ABL amplification in CML blast crisis following STI571 administration.

被引：0
|
作者：
Campbell, LJ
Patsouris, C
Rayeroux, KC
Somana, K
Januszewicz, H
机构：
[1] St Vincents Hosp, Victorian Canc Cytogenet Serv, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4435
引用
收藏
页码：185B / 185B
页数：1
相关论文
共 50 条
  • [1] STI571: Targeting BCR-ABL as therapy for CML
    Mauro, MJ
    Druker, BJ
    ONCOLOGIST, 2001, 6 (03): : 233 - 238
  • [2] AN APPROACH TO OVERCOME BCR-ABL INDEPENDENT STI571 RESISTANCE IN CML
    Rabizadeh, E.
    Aviram, A.
    Belyaeva, I.
    Merkin, V.
    Avissar, N.
    Shaklai, M.
    Zimra, Y.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 131 - 131
  • [3] STI571:: Bcr-Abl kinase inhibition as the basis of therapy for CML
    Mauro, MJ
    Druker, BJ
    LEUKEMIA, 2001, 15 (03) : 488 - 488
  • [4] Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia (CML) blast crisis.
    Mahon, FX
    Belloc, F
    Cholet, C
    Cony-Makhoul, P
    Guilhot, F
    Melo, JV
    Berthaud, P
    Reiffers, J
    BLOOD, 2000, 96 (11) : 471A - 471A
  • [5] Successful allogeneic transplantation after treatment of blast crisis CML with STI571
    Deininger, MWN
    Schäfer, K
    Sayer, H
    Russel, N
    Peschel, C
    Gratwohl, A
    Goldman, J
    Hochhaus, A
    Guilhot, F
    Gambacorti-Passerini, C
    O'Brian, S
    Arcese, W
    Kolb, H
    AlAli, H
    Hegenbart, U
    Lange, T
    Capdeville, R
    Niederwieser, D
    BONE MARROW TRANSPLANTATION, 2001, 27 : S37 - S38
  • [6] Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
    Sirulink, A
    Silver, RT
    Najfeld, V
    LEUKEMIA, 2001, 15 (11) : 1795 - 1797
  • [7] Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571
    A Sirulink
    RT Silver
    V Najfeld
    Leukemia, 2001, 15 : 1795 - 1797
  • [8] Serial molecular analysis of bcr-abl expression and chimerism status in CML patients following STI571 treatment.
    Gately, K
    Ryan, J
    McCann, S
    Howard, J
    Stallings, R
    Carroll, P
    Browne, P
    Conneally, E
    Lawler, M
    BRITISH JOURNAL OF CANCER, 2002, 86 : S88 - S89
  • [9] BCR-ABL gene amplification causes reversible cytogentic relapse and resistance to imatinib (STI571) in a chronic phase CML patient
    Gambacorti-Passeri, C
    Bambacorti-Passeri, C
    Bungaro, S
    Cazzanagi, G
    Piazza, R
    Tornaghi, L
    Pogliani, E
    Alberti, D
    Bondi, A
    Varella-Garcia, M
    Corneo, G
    BLOOD, 2002, 100 (11) : 216B - 216B
  • [10] STI571 as a targeted therapy for CML
    O'Dwyer, ME
    Mauro, MJ
    Druker, BJ
    CANCER INVESTIGATION, 2003, 21 (03) : 429 - 438
12345